The inhibition of these receptors may presumably be associated with rhabdomyolysis (hOTCN2), severe drug adverse reactions (ASBT), drug–drug interactions (hPEPT1 or P-gp), and colon cancer (ASBT). The gene discussed is SLC15A1; the disease is rhabdomyolysis.